USPTO serial 79075484
KARGLENI
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- SINGH, TEJBIR
- Law office
- TMEG LAW OFFICE 106
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KARGLENI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, diabetes, obesity, cancer, endocrine disorders, hormonal diseases and disorders, urological disorders, sexual dysfunction, HIV and AIDS, central nervous systems diseases and disorders, peripheral nervous system diseases and disorders, osteoporosis, rheumatism, neurological disorders, pain, gastrointestinal disorders, respiratory diseases and disorders, allergies, bacterial disorders, viral disorders, fungal disorders, infectious diseases, inflammation and inflammatory diseases, sepsis, immunological disorders, musculoskeletal disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 28, 2010 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jan 26, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 22, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 16, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 7, 2009 | LIMS | LIMITATION OF GOODS/SERVICES FROM IB ENTERED | — |
| Dec 4, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |